Gut Microbiota: Its Potential Roles in Pancreatic Cancer

被引:45
作者
Li, Quanxiao [1 ]
Jin, Meng [2 ]
Liu, Yahui [1 ]
Jin, Limin [3 ]
机构
[1] First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Peoples R China
[2] Sun Yat Sen Univ, Affliated Hosp 1, Dept Radiat Oncol, Guangzhou, Peoples R China
[3] First Hosp Jilin Univ, Dept Anesthesia, Changchun, Peoples R China
关键词
gut microbiota; pancreatic cancer; inflammation; immune response; immunotherapy; INTESTINAL BACTERIAL OVERGROWTH; INNATE IMMUNE-SYSTEM; PERIODONTAL-DISEASE; TUMOR MICROBIOME; MULTI-OMICS; RISK; CHEMOTHERAPY; ASSOCIATION; INDUCTION; OBESITY;
D O I
10.3389/fcimb.2020.572492
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pancreatic cancer is considered a lethal disease with a low survival rate due to its late-stage diagnosis, few opportunities for resection and lack of effective therapeutic strategies. Multiple, highly complex effects of gut microbiota on pancreatic cancer have been recognized as potential strategies for targeting tumorigenesis, development and treatment in recent decades; some of the treatments include antibiotics, probiotics, and fecal microbiota transplantation. Several bacterial species are associated with carcinogenesis of the pancreas, while some bacterial metabolites contribute to tumor-associated low-grade inflammation and immune responses via several proinflammatory factors and signaling pathways. Given the limited evidence on the interplay between gut microbiota and pancreatic cancer, risk factors associated with pancreatic cancer, such as diabetes, chronic pancreatitis and obesity, should also be taken into consideration. In terms of treatment of pancreatic cancer, gut microbiota has exhibited multiple effects on both traditional chemotherapy and the recently successful immunotherapy. Therefore, in this review, we summarize the latest developments and advancements in gut microbiota in relation to pancreatic cancer to elucidate its potential value.
引用
收藏
页数:9
相关论文
共 85 条
[1]   Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality [J].
Ahn, Jiyoung ;
Segers, Stephanie ;
Hayes, Richard B. .
CARCINOGENESIS, 2012, 33 (05) :1055-1058
[2]   Gut microbiota modulation of chemotherapy efficacy and toxicity [J].
Alexander, James L. ;
Wilson, Ian D. ;
Teare, Julian ;
Marchesi, Julian R. ;
Nicholson, Jeremy K. ;
Kinross, James M. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (06) :356-365
[3]  
American Cancer Society, 2020, CANC FACTS FIG 2020
[4]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[5]   The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL [J].
Aykut, Berk ;
Pushalkar, Smruti ;
Chen, Ruonan ;
Li, Qianhao ;
Abengozar, Raquel ;
Kim, Jacqueline I. ;
Shadaloey, Sorin A. ;
Wu, Dongling ;
Preiss, Pamela ;
Verma, Narendra ;
Guo, Yuqi ;
Saxena, Anjana ;
Vardhan, Mridula ;
Diskin, Brian ;
Wang, Wei ;
Leinwand, Joshua ;
Kurz, Emma ;
Rossi, Juan A. Kochen ;
Hundeyin, Mautin ;
Zambrinis, Constantinos ;
Li, Xin ;
Saxena, Deepak ;
Miller, George .
NATURE, 2019, 574 (7777) :264-+
[6]   Structural requirements for TLR4-mediated LPS signalling:: a biological role for LPS modifications [J].
Bäckhed, F ;
Normark, S ;
Schweda, EKH ;
Oscarson, S ;
Richter-Dahlfors, A .
MICROBES AND INFECTION, 2003, 5 (12) :1057-1063
[7]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[8]   History of Peptic Ulcer Disease and Pancreatic Cancer Risk in Men [J].
Bao, Ying ;
Spiegelman, Donna ;
Li, Ruifeng ;
Giovannucci, Edward ;
Fuchs, Charles S. ;
Michaud, Dominique S. .
GASTROENTEROLOGY, 2010, 138 (02) :541-549
[9]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[10]   Human gut microbiome: hopes, threats and promises [J].
Cani, Patrice D. .
GUT, 2018, 67 (09) :1716-1725